Concealed role of red blood cells in pathogenesis of pulmonary arterial hypertension: Decreased red blood cell nitric oxide generation and effect of Rho-Kinase inhibitor fasudil
Restricted accessResearch articleFirst published online January 11, 2021
Concealed role of red blood cells in pathogenesis of pulmonary arterial hypertension: Decreased red blood cell nitric oxide generation and effect of Rho-Kinase inhibitor fasudil
Pulmonary arterial hypertension (PAH) is a devastating disease characterized with alterations in pulmonary vasculature yielding increased pulmonary arterial resistance. Emerging evidences suggest important regulatory roles of red blood cells (RBCs) on nitric oxide (NO) bioavailability, mainly by modulating their endothelial nitric oxide synthase (eNOS) enzyme activity.
OBJECTIVE:
The aim of this pilot study was to evaluate the alterations in RBC eNOS activity and intracellular NO generation in PAH patients and the modulatory effects of Rho-Kinase (ROCK) inhibitors.
METHODS:
RBCs were isolated from patients with PAH and age-matched healthy subjects and were analyzed for their eNOS activity and NO generation capacity under the conditions of the presence or absence of ROCK inhibitor, fasudil. Phosphotidylserine (PS) exposure was also defined.
RESULTS:
eNOS activity and intracellular NO generation were lower in RBC from PAH patients. ROCK inhibitor increased basal eNOS activity and improved NO generation capacity of RBC of PAH patients to healthy control levels. PS exposure levels were also higher in RBC of PAH patients.
CONCLUSIONS:
This study provides first evidences for decreased RBC eNOS activity due to its ROCK mediated negative regulation in PAH patients. Considering increased ROCK activity contribution to progression of PAH, ROCK inhibition influences NO bioavailability through RBC eNOS, in addition to endothelial eNOS.
MontaniD, GuntherS, DorfmullerP, PerrosF, GirerdB, GarciaG, et al.Pulmonary arterial hypertension. Orphanet Journal of Rare Diseases. 2013;8:97.
2.
MathewR, HuangJ, GewitzMH. Pulmonary artery hypertension: caveolin-1 and eNOS interrelationship: a new perspective. Cardiology in Review. 2007;15(3):143–9.
3.
TournierA, WahlD, ChaouatA, MaxJP, RegnaultV, LecompteT, et al.Calibrated automated thrombography demonstrates hypercoagulability in patients with idiopathic pulmonary arterial hypertension. Thrombosis Research. 2010;126(6):e418–22.
4.
BudhirajaR, TuderRM, HassounPM. Endothelial dysfunction in pulmonary hypertension. Circulation. 2004;109(2):159–65.
5.
RanchouxB, HarveyLD, AyonRJ, BabichevaA, BonnetS, ChanSY, et al.Endothelial dysfunction in pulmonary arterial hypertension: an evolving landscape (2017 Grover Conference Series). Pulmonary Circulation. 2018;8(1):2045893217752912.
6.
KlingerJR, AbmanSH, GladwinMT. Nitric oxide deficiency and endothelial dysfunction in pulmonary arterial hypertension. Am J Respir Crit Care Med. 2013;188(6):639–46.
7.
IannoneL, ZhaoL, DuboisO, DulucL, RhodesCJ, WhartonJ, et al.miR-21/DDAH1 pathway regulates pulmonary vascular responses to hypoxia. The Biochemical Journal. 2014;462(1):103–12.
8.
GhoshS, GuptaM, XuW, MavrakisDA, JanochaAJ, ComhairSA, et al.Phosphorylation inactivation of endothelial nitric oxide synthesis in pulmonary arterial hypertension. American Journal of Physiology Lung Cellular and Molecular Physiology.L. 2016;310(11):1199–205.
9.
WeerackodyRP, WelshDJ, WadsworthRM, PeacockAJ. Inhibition of p38 MAPK reverses hypoxia-induced pulmonary artery endothelial dysfunction. American Journal of Physiology Heart and Circulatory Physiology. 2009;296(5):H1312–20.
10.
DiederichL, SuvoravaT, SansoneR, KellerTCSt, BarbarinoF, SuttonTR, et al.On the Effects of Reactive Oxygen Species and Nitric Oxide on Red Blood Cell Deformability. Frontiers in Physiology. 2018;9:332.
11.
MouchaersKT, SchalijI, deBoer MA, PostmusPE, vanHinsbergh VW, vanNieuw Amerongen GP, et al.Fasudil reduces monocrotaline-induced pulmonary arterial hypertension: comparison with bosentan and sildenafil. The European Respiratory Journal. 2010;36(4):800–7.
12.
FukumotoY, YamadaN, MatsubaraH, MizoguchiM, UchinoK, YaoA, et al.Double-blind, placebo-controlled clinical trial with a rho-kinase inhibitor in pulmonary arterial hypertension. Circ J. 2013;77(10):2619–25.
13.
ZhuangR, WuJ, LinF, HanL, LiangX, MengQ, et al.Fasudil preserves lung endothelial function and reduces pulmonary vascular remodeling in a rat model of endstage pulmonary hypertension with left heart disease. International Journal of Molecular Medicine. 2018;42(3):1341–52.
14.
AbeK, ShimokawaH, MorikawaK, UwatokuT, OiK, MatsumotoY, et al.Long-term treatment with a Rho-kinase inhibitor improves monocrotaline-induced fatal pulmonary hypertension in rats. Circulation Research. 2004;94(3):385–93.
15.
XiaoJW, ZhuXY, WangQG, ZhangDZ, CuiCS, ZhangP, et al.Acute effects of Rho-kinase inhibitor fasudil on pulmonary arterial hypertension in patients with congenital heart defects. Circ J. 2015;79(6):1342–8.
16.
RuanH, ZhangY, LiuR, YangX. The acute effects of 30 mg vs 60 mg of intravenous Fasudil on patients with congenital heart defects and severe pulmonary arterial hypertension. Congenital Heart Disease. 2019;14(4):645–50.
17.
SchwenkeDO, PearsonJT, SonobeT, Ishibashi-UedaH, ShimouchiA, KangawaK, et al.Role of Rho-kinase signaling and endothelial dysfunction in modulating blood flow distribution in pulmonary hypertension. Journal of Applied Physiology. 2011;110(4):901–8.
18.
JiangX, WangYF, ZhaoQH, JiangR, WuY, PengFH, et al.Acute hemodynamic response of infused fasudil in patients with pulmonary arterial hypertension: a randomized, controlled, crossover study. Int J Cardiol. 2014;177(1):61–5.
19.
JiangR, AiZS, JiangX, YuanP, LiuD, ZhaoQH, et al.Intravenous fasudil improves in-hospital mortality of patients with right heart failure in severe pulmonary hypertension. Hypertension Research: Official Journal of the Japanese Society of Hypertension. 2015;38(8):539–44.
20.
ZhangX, ZhangX, WangS, LuoJ, ZhaoZ, ZhengC, et al.Effects of Fasudil on Patients with Pulmonary Hypertension Associated with Left Ventricular Heart Failure with Preserved Ejection Fraction: A Prospective Intervention Study. Canadian Respiratory Journal. 2018;2018:3148259.
21.
Elias-Al-MamunM, SatohK, TanakaS, ShimizuT, NerguiS, MiyataS, et al.Combination therapy with fasudil and sildenafil ameliorates monocrotaline-induced pulmonary hypertension and survival in rats. Circulation Journal: Official Journal of the Japanese Circulation Society. 2014;78(4):967–76.
22.
SmithTG, BalanosGM, CroftQP, TalbotNP, DorringtonKL, RatcliffePJ, et al.The increase in pulmonary arterial pressure caused by hypoxia depends on iron status. The Journal of Physiology. 2008;586(24):5999–6005.
23.
BalanosGM, DorringtonKL, RobbinsPA. Desferrioxamine elevates pulmonary vascular resistance in humans: potential for involvement of HIF-1. J Appl Physiol (1985). 2002;92(6):2501–7.
24.
KleinbongardP, SchulzR, RassafT, LauerT, DejamA, JaxT, et al.Red blood cells express a functional endothelial nitric oxide synthase. Blood. 2006;107(7):2943–51.
25.
HorobinJT, WatanabeN, HakozakiM, SabapathyS, SimmondsMJ. Shear-stress mediated nitric oxide production within red blood cells: A dose-response. Clinical Hemorheology and Microcirculation. 2019;71(2):203–14.
26.
UlkerP, YarasN, YalcinO, Celik-OzenciC, JohnsonPC, MeiselmanHJ, et al.Shear stress activation of nitric oxide synthase and increased nitric oxide levels in human red blood cells. Nitric Oxide. 2011;24(4):184–91.
27.
KuckL, GrauM, BlochW, SimmondsMJ. Shear Stress Ameliorates Superoxide Impairment to Erythrocyte Deformability With Concurrent Nitric Oxide Synthase Activation. Frontiers in Physiology. 2019;10:36.
28.
Cortese-KrottMM, KelmM. Endothelial nitric oxide synthase in red blood cells: key to a new erythrocrine function? Redox Biology (2014;2:251–8.
29.
Cortese-KrottMM, Rodriguez-MateosA, SansoneR, KuhnleGG, Thasian-SivarajahS, KrenzT, et al.Human red blood cells at work: identification and visualization of erythrocytic eNOS activity in health and disease. Blood. 2012;120(20):4229–37.
30.
Cortese-KrottMM, MergiaE, KramerCM, LuckstadtW, YangJ, WolffG, et al.Identification of a soluble guanylate cyclase in RBCs: preserved activity in patients with coronary artery disease. Redox Biology. 2018;14:328–37.
31.
YangJ, GononAT, SjoquistPO, LundbergJO, PernowJ. Arginase regulates red blood cell nitric oxide synthase and export of cardioprotective nitric oxide bioactivity. Proceedings of the National Academy of Sciences of the United States of America. 2013;110(37):15049–54.
32.
UlkerP, GunduzF, MeiselmanHJ, BaskurtOK. Nitric oxide generated by red blood cells following exposure to shear stress dilates isolated small mesenteric arteries under hypoxic conditions. Clin Hemorheol Microcirc. 2013;54(4):357–69.
33.
YangJ, ZhengX, MahdiA, ZhouZ, TratsiakovichY, JiaoT, et al.Red Blood Cells in Type 2 Diabetes Impair Cardiac Post-Ischemic Recovery Through an Arginase-Dependent Modulation of Nitric Oxide Synthase and Reactive Oxygen Species. JACC Basic to Translational Science. 2018;3(4):450–63.
34.
ZhouZ, MahdiA, TratsiakovichY, ZahoranS, KovameesO, NordinF, et al.Erythrocytes From Patients With Type 2 Diabetes Induce Endothelial Dysfunction Via Arginase I. Journal of the American College of Cardiology. 2018;72(7):769–80.
35.
PernowJ, MahdiA, YangJ, ZhouZ. Red blood cell dysfunction: a new player in cardiovascular disease. Cardiovascular Research. 2019;115(11):1596–605.
36.
RotherRP, BellL, HillmenP, GladwinMTJama. 2005;293(13):1653–62The clinical sequelae of intravascular hemolysis and extracellular plasma hemogloba novel mechanism of human disease.
37.
DonadeeC, RaatNJ, KaniasT, TejeroJ, LeeJS, KelleyEE, et al.Nitric oxide scavenging by red blood cell microparticles and cell-free hemoglobin as a mechanism for the red cell storage lesion. Circulation. 2011;124(4):465–76.
38.
ChangAE, DetarR. Oxygen and vascular smooth muscle contraction revisited. The American Journal of Physiology. 1980;238(5):H716–28.
39.
SpragueRS, StephensonAH, DimmittRA, WeintraubNL, BranchCA, McMurdoL, et al.Effect of L-NAME on pressure-flow relationships in isolated rabbit lungs: role of red blood cells. The American Journal of Physiology. 1995;269(6 Pt 2):H1941–8.
40.
GalieN, HumbertM, VachieryJL, GibbsS, LangI, TorbickiA, et al.ESC/ERS Guidelines for the diagnosis and treatment of pulmonary hypertension: The Joint Task Force for the Diagnosis and Treatment of Pulmonary Hypertension of the European Society of Cardiology (ESC) and the European Respiratory Society (ERS): Endorsed by: Association for European Paediatric and Congenital Cardiology (AEPC), International Society for Heart and Lung Transplantation (ISHLT). Eur Heart J. 2016;37(1):67–119.
41.
KaymazC, MutluB, KucukogluMS, KayaB, AkdenizB, KilickiranAvci B, et al.Preliminary results from a nationwide adult cardiology perspective for pulmonary hypertension: RegiStry on clInical outcoMe and sUrvival in pulmonaRy hypertension Groups (SIMURG). Anatolian Journal of Cardiology. 2017;18(4):242–50.
42.
FaganKA, McMurtryI, RodmanDM. Nitric oxide synthase in pulmonary hypertension: lessons from knockout mice. Physiological Research. 2000;49(5):539–48.
43.
GirgisRE, ChampionHC, DietteGB, JohnsRA, PermuttS, SylvesterJT. Decreased exhaled nitric oxide in pulmonary arterial hypertension: response to bosentan therapy. Am J Respir Crit Care Med. 2005;172(3):352–7.
44.
KanekoFT, ArroligaAC, DweikRA, ComhairSA, LaskowskiD, OppedisanoR, et al.Biochemical reaction products of nitric oxide as quantitative markers of primary pulmonary hypertension. Am J Respir Crit Care Med. 1998;158(3):917–23.
45.
ChampionHC, BivalacquaTJ, GreenbergSS, GilesTD, HymanAL, KadowitzPJ. Adenoviral gene transfer of endothelial nitric-oxide synthase (eNOS) partially restores normal pulmonary arterial pressure in eNOS-deficient mice. Proc Natl Acad Sci U S A. 2002;99(20):13248–53.
46.
FaganKA, FoutyBW, TylerRC, MorrisKG, Jr. , Hepler LK, Sato K, et al. The pulmonary circulation of homozygous or heterozygous eNOS-null mice is hyperresponsive to mild hypoxia. The Journal of Clinical Investigation. 1999;103(2):291–9.
47.
SteudelW, IchinoseF, HuangPL, HurfordWE, JonesRC, BevanJA, et al.Pulmonary vasoconstriction and hypertension in mice with targeted disruption of the endothelial nitric oxide synthase (NOS 3) gene. Circulation Research. 1997;81(1):34–41.
48.
XuW, KanekoFT, ZhengS, ComhairSA, JanochaAJ, GoggansT, et al.Increased arginase II and decreased NO synthesis in endothelial cells of patients with pulmonary arterial hypertension. FASEB Journal: Official Publication of the Federation of American Societies for Experimental Biology. 2004;18(14):1746–8.
49.
HeissEH, DirschVM. Regulation of eNOS enzyme activity by posttranslational modification. Current Pharmaceutical Design. 2014;20(22):3503–13.
50.
FlemingI, BusseR. Signal transduction of eNOS activation. Cardiovasc Res. 1999;43(3):532–41.
51.
WeiH, ZhangD, LiuL, XiaW, LiF. Rho signaling pathway enhances proliferation of PASMCs by suppressing nuclear translocation of Smad1 in PAH. Experimental and Therapeutic Medicine. 2019;17(1):71–8.
52.
YaoL, RomeroMJ, ToqueHA, YangG, CaldwellRB, CaldwellRW. The role of RhoA/Rho kinase pathway in endothelial dysfunction. Journal of Cardiovascular Disease Research. 2010;1(4):165–70.
53.
ForstermannU, MunzelT. Endothelial nitric oxide synthase in vascular disease: from marvel to menace. Circulation. 2006;113(13):1708–14.
54.
Loirand G. Rho Kinases in Health and Disease: From Basic Science to Translational Research. Pharmacological Reviews. 2015;67(4):1074–95.
55.
OkaM, HommaN, Taraseviciene-StewartL, MorrisKG, KraskauskasD, BurnsN, et al.Rho kinase-mediated vasoconstriction is important in severe occlusive pulmonary arterial hypertension in rats. Circulation Research. 2007;100(6):923–9.
56.
FukumotoY, MatobaT, ItoA, TanakaH, KishiT, HayashidaniS, et al.Acute vasodilator effects of a Rho-kinase inhibitor, fasudil, in patients with severe pulmonary hypertension. Heart. 2005;91(3):391–2.
57.
FujitaH, FukumotoY, SajiK, SugimuraK, DemachiJ, NawataJ, et al.Acute vasodilator effects of inhaled fasudil, a specific Rho-kinase inhibitor, in patients with pulmonary arterial hypertension. Heart and Vessels. 2010;25(2):144–9.
58.
MingXF, ViswambharanH, BarandierC, RuffieuxJ, KaibuchiK, RusconiS, et al.Rho GTPase/Rho kinase negatively regulates endothelial nitric oxide synthase phosphorylation through the inhibition of protein kinase B/Akt in human endothelial cells. Molecular and Cellular Biology. 2002;22(24):8467–77.
59.
ChandraS, RomeroMJ, ShatanawiA, AlkilanyAM, CaldwellRB, CaldwellRW. Oxidative species increase arginase activity in endothelial cells through the RhoA/Rho kinase pathway. British Journal of Pharmacology. 2012;165(2):506–19.
60.
WesselingMC, Wagner-BritzL, HuppertH, HanfB, HertzL, NguyenDB, et al.Phosphatidylserine Exposure in Human Red Blood Cells Depending on Cell Age. Cellular Physiology and Biochemistry: International Journal of Experimental Cellular Physiology, Biochemistry, and Pharmacology. 2016;38(4):1376–90.
